Cases & Deals

  • Home
  • Practices
  • AbbVie develops patent portfolio related to anti-CD71 Probody™ Drug Conjugates

Share

AbbVie develops patent portfolio related to anti-CD71 Probody™ Drug Conjugates

February 2021

Client(s) AbbVie Inc.

Jones Day is representing AbbVie Inc. in connection with the development of a global patent portfolio related to Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1).

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.